SCHEMBL1749262

SCHEMBL1749262

COc1cc2c(-c3cc4c(CNc5ccccc5)ccnc4[nH]3)cn(C)c2cc1OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 3/20 0.60
GSK3B P49841 4/20 0.44
GSK3A P49840 3/20 0.44
CDK7 P50613 3/20 0.44
LRRK2 Q5S007 3/20 0.44
AURKB Q96GD4 3/20 0.44
LCK P06239 2/20 0.44
JAK2 O60674 2/20 0.44
BTK Q06187 1/20 0.44
CDK9 P50750 6/20 0.37
CDK5 Q00535 3/20 0.37
CLK4 Q9HAZ1 3/20 0.37
MAPK8 P45983 2/20 0.37
AURKA O14965 2/20 0.37
ABL1 P00519 2/20 0.37
RET P07949 2/20 0.37
FLT3 P36888 2/20 0.37
LIMK1 P53667 2/20 0.37
PRKAA1 Q13131 2/20 0.37
CHUK O15111 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1748950 0.88 IGF1R (0.59) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749485 0.86 IGF1R (0.51) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749493 0.86 IGF1R (0.51) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749159 0.85 IGF1R (0.56) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749106 0.85 IGF1R (0.50) IGF1RJAK2CDK9TBK1MAPT
SCHEMBL1750116 0.85 IGF1R (0.56) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1748818 0.84 IGF1R (0.64) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749523 0.84 IGF1R (0.64) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1749253 0.84 IGF1R (0.55) IGF1RGSK3BGSK3ACDK7LRRK2
SCHEMBL1748739 0.83 IGF1R (0.57) IGF1RGSK3BGSK3ACDK7LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed
CN-1950083-A Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA SA (FR) 2007-04-18 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885GSK3B 536/4885GSK3A 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.